Target intelligence / Profile preview

Respiratory syncytial virus fusion protein heptad repeat B pocket (RSV F HRB pocket)

Target
RSV F HRB pocket
Molecular classification
Viral fusion protein, Class I fusion protein, Glycoprotein
01

Overview

The Respiratory syncytial virus (RSV) fusion (F) protein is a Class I viral fusion protein essential for the entry of the virus into host cells by mediating the fusion of the viral envelope with the host cell membrane. It exists as a metastable prefusion trimer that, upon triggering, undergoes a massive conformational rearrangement into a stable postfusion state, characterized by the formation of a six-helix bundle (6HB) where three C-terminal heptad repeat B (HRB) helices pack into the grooves of a central N-terminal heptad repeat A (HRA) coiled-coil. The heptad repeat B pocket refers to a hydrophobic cavity within the central core of the prefusion F protein trimer, involving residues from the HRB region and the fusion peptide. This pocket is a critical therapeutic target for small-molecule fusion inhibitors, such as presatovir and ziresovir, which bind to this site to stabilize the prefusion conformation and prevent the structural transition required for membrane fusion. Targeting this pocket effectively blocks viral infection and the formation of syncytia, making it a primary focus for the development of RSV antivirals.

Other names
RSV F protein central cavityRSV F protein fusion inhibitor binding pocketRSV F protein HRB-binding siteRespiratory syncytial virus fusion glycoproteinRSV F1 subunit heptad repeat B pocket
02

Mechanism of action

Small-molecule fusion inhibitors bind to the central cavity (HRB pocket) of the prefusion RSV F protein trimer, stabilizing the metastable prefusion conformation and preventing the structural rearrangement into the postfusion six-helix bundle (6HB), thereby blocking viral-host membrane fusion.

03

Biological functions

Viral entryMembrane fusionSyncytia formationViral attachment
04

Disease associations

Respiratory syncytial virus infectionBronchiolitisPneumoniaLower respiratory tract infection
05

Safety considerations

Rapid emergence of viral resistance mutations (e.g., F488L, D486N)Clinical efficacy challenges in diverse populations (infants, elderly, immunocompromised)Potential for long tissue retention (observed in early candidates like JNJ-2408068)
06

Interacting drugs

Presatovir (GS-5806)

9 more in the full profile.

07

Biomarkers

RSV RNA viral loadRSV F protein sequence (resistance mutations at residues 140, 141, 398, 486, 487, 488, 489)RSV subtype (A or B)

Beyond the preview

Go deeper on Respiratory syncytial virus fusion protein heptad repeat B pocket (RSV F HRB pocket).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Respiratory syncytial virus fusion protein heptad repeat B pocket (RSV F HRB pocket).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call